<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Physiol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Physiol Rep</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2051-817X</journal-id><journal-id journal-id-type="publisher-id">PHY2</journal-id><journal-id journal-id-type="hwp">physreports</journal-id><journal-title-group><journal-title>Physiological Reports</journal-title></journal-title-group><issn pub-type="epub">2051-817X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6328912</article-id><article-id pub-id-type="doi">10.14814/phy2.13951</article-id><article-id pub-id-type="publisher-id">PHY213951</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Urinary T cells correlate with rate of renal function loss in autosomal dominant polycystic kidney disease</article-title><alt-title alt-title-type="left-running-head">K. A. Zimmerman <italic>et&#160;al</italic>.</alt-title></title-group><contrib-group><contrib id="phy213951-cr-0001" contrib-type="author"><name><surname>Zimmerman</surname><given-names>Kurt A.</given-names></name><xref ref-type="aff" rid="phy213951-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="phy213951-cr-0002" contrib-type="author"><name><surname>Gonzalez</surname><given-names>Nancy M.</given-names></name><xref ref-type="aff" rid="phy213951-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="phy213951-cr-0003" contrib-type="author"><name><surname>Chumley</surname><given-names>Phillip</given-names></name><xref ref-type="aff" rid="phy213951-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="phy213951-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="phy213951-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="phy213951-cr-0004" contrib-type="author"><name><surname>Chacana</surname><given-names>Teresa</given-names></name><xref ref-type="aff" rid="phy213951-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="phy213951-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="phy213951-cr-0005" contrib-type="author"><name><surname>Harrington</surname><given-names>Laurie E.</given-names></name><xref ref-type="aff" rid="phy213951-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="phy213951-cr-0006" contrib-type="author"><name><surname>Yoder</surname><given-names>Bradley K.</given-names></name><xref ref-type="aff" rid="phy213951-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="phy213951-cr-0007" contrib-type="author" corresp="yes"><name><surname>Mrug</surname><given-names>Michal</given-names></name><address><email>mmrug@uab.ed</email></address><xref ref-type="aff" rid="phy213951-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="phy213951-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="phy213951-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="phy213951-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Cell, Developmental and Integrative Biology</named-content>
<institution>The University of Alabama at Birmingham</institution>
<named-content content-type="city">Birmingham</named-content>
<named-content content-type="country-part">Alabama</named-content>
</aff><aff id="phy213951-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>The University of Alabama at Birmingham</institution>
<named-content content-type="city">Birmingham</named-content>
<named-content content-type="country-part">Alabama</named-content>
</aff><aff id="phy213951-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Nephrology Research and Training Center</named-content>
<institution>The University of Alabama at Birmingham</institution>
<named-content content-type="city">Birmingham</named-content>
<named-content content-type="country-part">Alabama</named-content>
</aff><aff id="phy213951-aff-0004">
<label><sup>4</sup></label>
<institution>Department of Veterans Affairs Medical Center</institution>
<named-content content-type="city">Birmingham</named-content>
<named-content content-type="country-part">Alabama</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Michal Mrug, Division Nephrology, University of Alabama at Birmingham, 1900 University Blvd, THT 611J, Birmingham, AL 35294.<break/>
Tel: +1 (205) 934&#8208;9509<break/>
Fax: +1 (205) 934&#8208;1879<break/>
E&#8208;mail: <email>mmrug@uab.ed</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2019</year></pub-date><volume>7</volume><issue>1</issue><issue-id pub-id-type="doi">10.1002/phy2.2019.7.issue-1</issue-id><elocation-id>e13951</elocation-id><history><date date-type="received"><day>30</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 Published by the Physiological Society and the American Physiological Society <copyright-statement>--><copyright-statement content-type="article-copyright">&#169; 2019 The Authors. <italic>Physiological Reports</italic> published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:PHY2-7-e13951.pdf"/><abstract id="phy213951-abs-0001"><title>Abstract</title><p>Several innate immune response components were recognized as outcome predictors in autosomal dominant polycystic kidney disease (<styled-content style="fixed-case">ADPKD</styled-content>) and their causative role in disease pathogenesis was confirmed in animal models. In contrast, the role of adaptive immunity in <styled-content style="fixed-case">ADPKD</styled-content> remains relatively unexplored. Therefore, we evaluated T cell populations in kidney and urine of <styled-content style="fixed-case">ADPKD</styled-content> patients using flow cytometry and confocal immunofluorescence microscopy approaches. These analyses revealed <styled-content style="fixed-case">ADPKD</styled-content>&#8208;associated overall increases in the number of intrarenal <styled-content style="fixed-case">CD</styled-content>4 and <styled-content style="fixed-case">CD</styled-content>8 T cells that were associated with a loss of polarity in distribution between the cortex and medulla (higher in medulla vs. cortex in controls). Also, the urinary T cell&#8208;based index correlated moderately with renal function decline in a small cohort of <styled-content style="fixed-case">ADPKD</styled-content> patients. Together, these data suggest that similar to innate immune responses, T cells participate in <styled-content style="fixed-case">ADPKD</styled-content> pathogenesis. They also point to urinary T cells as a novel candidate marker of the disease activity in <styled-content style="fixed-case">ADPKD</styled-content>.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="phy213951-kwd-0001">Adaptive immunity</kwd><kwd id="phy213951-kwd-0002">cystic kidney disease</kwd><kwd id="phy213951-kwd-0003">T cell subpopulations, <styled-content style="fixed-case">eGFR</styled-content></kwd><kwd id="phy213951-kwd-0004">urine biomarker</kwd></kwd-group><funding-group><award-group><funding-source>National Institutes of Health</funding-source><award-id>R01 DK115752</award-id></award-group><award-group><funding-source>University of Alabama at Birmingham (UAB) Hepato/Renal Fibrocystic Disease Core Center</funding-source><award-id>P30&#8208;DK&#8208;074038</award-id><award-id>R01 DK097423</award-id><award-id>1&#8208;I01&#8208;BX002298</award-id><award-id>AMC21</award-id></award-group><award-group><funding-source>Office of Research and Development</funding-source></award-group><award-group><funding-source>Medical Research Service</funding-source></award-group><award-group><funding-source>Department of Veterans Affairs</funding-source></award-group><award-group><funding-source>Detraz Endowed Research Fund in Polycystic Kidney Disease</funding-source></award-group><award-group><funding-source>PKD Foundation</funding-source><award-id>214g16a</award-id></award-group><award-group><funding-source>National Institutes of Health T32 training grant in Basic Immunology and Immunologic disease</funding-source><award-id>2T32AI007051&#8208;38</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="8"/><word-count count="4605"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>phy213951</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.4 mode:remove_FC converted:11.01.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="phy213951-cit-1001">
<string-name>
<given-names>K. A.</given-names>
<surname>Zimmerman</surname>
</string-name>, <string-name>
<given-names>N. M.</given-names>
<surname>Gonzalez</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Chumley</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Chacana</surname>
</string-name>, <string-name>
<given-names>L. E.</given-names>
<surname>Harrington</surname>
</string-name>, <string-name>
<given-names>B. K.</given-names>
<surname>Yoder</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Mrug</surname>
</string-name>. <article-title>Urinary T cells correlate with rate of renal function loss in autosomal dominant polycystic kidney disease</article-title>. <source xml:lang="en">Physiol Rep</source>, <volume>7</volume> (<issue>1</issue>), <year>2019</year>, <elocation-id>e13951</elocation-id>, <pub-id pub-id-type="doi">10.14814/phy2.13951</pub-id>
</mixed-citation>
</p><fn-group id="phy213951-ntgp-0001"><fn fn-type="funding" id="phy213951-note-1001"><p>
<bold>Funding Information</bold>
</p><p>Support was provided in part by the National Institutes of Health (NIH)&#8208;funded University of Alabama at Birmingham (UAB) Hepato/Renal Fibrocystic Disease Core Center P30&#8208;DK&#8208;074038, R01 DK097423, 1&#8208;I01&#8208;BX002298 from the Office of Research and Development, Medical Research Service, Department of Veterans Affairs and by the Detraz Endowed Research Fund in Polycystic Kidney Disease (to M. M.). Additional support was provided by the PKD Foundation grant 214g16a (B.K.Y.); School of Medicine, University of Alabama at Birmingham AMC21 grant (B.K.Y., M.M.); National Institutes of Health T32 training grant in Basic Immunology and Immunologic disease 2T32AI007051&#8208;38 (K.A.Z.) and National Institutes of Health (NIH) R01 DK115752 (B.K.Y.).</p></fn></fn-group></notes></front><body><sec id="phy213951-sec-0001"><title>Introduction</title><p>Polycystic kidney diseases (PKD) are the most commonly inherited cause of end&#8208;stage renal disease (ESRD). Autosomal dominant PKD (ADPKD; MIM: 173900 and 613095) leads to ESRD in most patients in their 50's while autosomal recessive PKD (ARPKD; MIM: 263200) is a major cause of ESRD in children. Currently, the majority of PKD patients can only be offered supportive care that unfortunately has minimal impact on the onset of ESRD (Spithoven et&#160;al. <xref rid="phy213951-bib-0015" ref-type="ref">2014</xref>; Fernando et&#160;al. <xref rid="phy213951-bib-0004" ref-type="ref">2017</xref>).</p><p>Innate immune system abnormalities are a dominant feature of both ADPKD (Zeier et&#160;al. <xref rid="phy213951-bib-0019" ref-type="ref">1992</xref>) and ARPKD (Mrug et&#160;al. <xref rid="phy213951-bib-0013" ref-type="ref">2013b</xref>). However, until recently, the PKD&#8208;related innate immune response abnormalities were thought to be associated with advanced stages of disease progression without substantial impact on clinical outcomes. Discovery of abnormal urinary excretion of monocyte chemoattractant protein 1 (MCP&#8208;1; also called chemokine (C&#8208;C motif) ligand 2, CCL2) in early disease stages in ADPKD patients and animal models&#160;(Cowley et&#160;al. <xref rid="phy213951-bib-0002" ref-type="ref">2001</xref>; Zheng et&#160;al. <xref rid="phy213951-bib-0020" ref-type="ref">2003</xref>) changed this paradigm by demonstrating that innate immunity is altered early in the disease progression. Moreover, MCP&#8208;1, as well as a monocyte/macrophage marker CD14, were identified as candidate predictors of ADPKD outcomes (Grantham et&#160;al. <xref rid="phy213951-bib-0005" ref-type="ref">2010</xref>; Zhou et&#160;al. <xref rid="phy213951-bib-0021" ref-type="ref">2010</xref>). Importantly, the addition of urine MCP&#8208;1 data improved predictive models of renal function loss in ADPKD patients even when kidney volume, baseline kidney function, and demographic data were included in these models (Mrug et&#160;al. <xref rid="phy213951-bib-0012" ref-type="ref">2013a</xref>). In addition, several recent lines of evidence suggest that immune responses directly promote cystogenesis, at least in animal models (e.g., (Li et&#160;al. <xref rid="phy213951-bib-0010" ref-type="ref">2008</xref>; Mei et&#160;al. <xref rid="phy213951-bib-0011" ref-type="ref">2007</xref>; Shillingford et&#160;al. <xref rid="phy213951-bib-0014" ref-type="ref">2006</xref>)). Since the increase in macrophage markers precedes cyst formation in these models, the innate immune abnormalities may represent an early consequence of the underlying molecular PKD defect. Relevance of this concept was confirmed by studies showing that depletion of renal macrophages attenuated renal cystic disease progression in animal models (Karihaloo et&#160;al. <xref rid="phy213951-bib-0006" ref-type="ref">2011</xref>; Swenson&#8208;Fields et&#160;al. <xref rid="phy213951-bib-0016" ref-type="ref">2013</xref>). Since, prominent mononuclear infiltrates were also observed in ARPKD (Zhou et&#160;al. <xref rid="phy213951-bib-0021" ref-type="ref">2010</xref>; Swenson&#8208;Fields et&#160;al. <xref rid="phy213951-bib-0016" ref-type="ref">2013</xref>), the mononuclear cells likely participate in the disease pathogenesis through a common cystogenic pathway.</p><p>While mononuclear phagocytes including monocytes and macrophages represent central component of innate immune response, lymphocytes, another major renal immune cell type, are effector cells of adaptive immunity. Their subpopulations are engaged in complex, functionally relevant interactions with mononuclear phagocytes. Although renal interstitial lymphocytic infiltrates were described nearly three decades ago in patients with ADPKD (infiltrates of CD4 lymphocytes) (Zeier et&#160;al. <xref rid="phy213951-bib-0019" ref-type="ref">1992</xref>) and in renal cystic disease models (<italic>Nek1</italic>
<sup>kat2J</sup> and <italic>Nphp3</italic>
<sup>pcy</sup> mice and <italic>Anks6</italic>
<sup>Cy</sup> (Han:SPRD Cy rats) (Kaspareit&#8208;Rittinghausen et&#160;al. <xref rid="phy213951-bib-0007" ref-type="ref">1989</xref>; Takahashi et&#160;al. <xref rid="phy213951-bib-0017" ref-type="ref">1991</xref>; Vogler et&#160;al. <xref rid="phy213951-bib-0018" ref-type="ref">1999</xref>), systematic evaluation of lymphocytic subpopulations in ADPKD kidneys or their relevance in disease progression has not been reported. To advance this area of research, we characterized lymphocytic populations in kidneys from ADPKD patients. Also, inspired by recent description of urinary T cells as novel predictors of the disease activity in systemic lupus (SLE) (Enghard et&#160;al. <xref rid="phy213951-bib-0003" ref-type="ref">2009</xref>; Kopetschke et&#160;al. <xref rid="phy213951-bib-0009" ref-type="ref">2015</xref>), we adopted this method to analyze the association of urinary T cells with rate of decline in renal function in ADPKD patients.</p></sec><sec id="phy213951-sec-0002"><title>Materials and Methods</title><sec id="phy213951-sec-0003"><title>Kidney tissue and urine samples</title><p>Remnant human ADPKD and non&#8208;PKD kidney tissues and urines were collected, de&#8208;identified and analyzed according to a protocol approved by the Institutional Review Board of University of Alabama at Birmingham (UAB). All ADPKD tissues were obtained from patients with end&#8208;stage renal disease (all pretransplant). All non&#8208;PKD kidney tissues were collected from patients with intrarenal tumors; we collected normal&#8208;appearing tissues from a kidney pole opposite to a well&#8208;demarcated suspected malignancy; samples with large tumors were excluded. The glomerular filtration rate (eGFR) estimated by CKD&#8208;EPI formula in non&#8208;PKD controls was in the range of 54&#8211;107 (average 82) mL/min/1.73&#160;m<sup>2</sup> (Table&#160;<xref rid="phy213951-tbl-0001" ref-type="table">1</xref>). The average age of ADPKD patients was lower (52&#160;&#177;&#160;9&#160;years vs. 64&#160;&#177;&#160;20&#160;years for non&#8208;PKD controls; <italic>P</italic>&#160;=&#160;0.193). All tissues were processed after gross clinical pathology evaluation, within 4&#160;h after removal from patients. Specifically, we collected representative samples of renal cortex and medulla; renal cortex was obtained from less than a 1&#160;cm rim of tissue immediately under the renal capsule that contains glomeruli, renal medulla was collected from an approximately 2&#160;cm rim of tissue without glomeruli adjacent to renal pelvis (Fig.&#160;<xref rid="phy213951-fig-0001" ref-type="fig">1</xref>). Validity of such an approach was confirmed by the presence of glomeruli in tissues assigned to correspond to cortex and the absence of glomeruli in tissues assigned to medulla. Tissues from immediate subcapsular and corticomedullary regions as well as renal papilla were excluded. In the case of ADPKD renal tissues, we collected only the most preserved, normal&#8208;appearing parts of the kidneys with minimal amount of cysts or fibrosis present on gross evaluation (Fig.&#160;<xref rid="phy213951-fig-0001" ref-type="fig">1</xref>). Samples from patients with signs of systemic infection, renal infection, or renal/ureteral obstruction were excluded.</p><table-wrap id="phy213951-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical characteristics of analyzed kidney tissues</p></caption><table-wrap-foot><fn id="phy213951-note-0002"><p>Control versus ADPKD: <italic>P</italic>&#160;&lt;&#160;0.01 (**); <italic>P</italic>&#160;&lt;&#160;0.001 (***).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="phy213951-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Examples of <styled-content style="fixed-case">ADPKD</styled-content> and control renal tissues. Representative hematoxylin and eosin&#8208;stained sections of tissues that were used in our study. These tissues contain relatively small amount of microscopic cysts and fibrosis because they were collected from normal&#8208;appearing compartments of <styled-content style="fixed-case">ADPKD</styled-content> kidneys. Scale bar&#160;=&#160;1&#160;cm.</p></caption><graphic id="nlm-graphic-3" xlink:href="PHY2-7-e13951-g001"/></fig><p>The remnant urine samples were procured and analyzed within 2&#8211;4&#160;h of collection using the same flow cytometry technique as used for kidney tissues. Relevant demographic, laboratory, and imaging data were recorded; results that were not obtained at the time of the urine collection (e.g., kidney size) were based on time&#8208;adjusted earlier measurements. Samples from patients with suspected systemic, renal, or urinary tract infection based on history, exam, laboratory, or imaging studies (including urinalysis) were excluded.</p></sec><sec id="phy213951-sec-0004"><title>Flow cytometry of T cells from kidney tissues</title><p>The flow cytometry analyses were done on at least 3&#160;g of renal cortex or medulla tissue (combined from multiple regions of the same kidney to reduce the selection bias). Each tissue was finely minced using a razor blade and incubated for 30&#160;min in 5&#160;mL of RPMI 1640 media (ThermoFisher Scientific) containing 1&#160;mg/mL collagenase (Catalog#: C0130, Sigma&#8208;Aldrich, St. Louis, MO) and 100&#160;U/mL of DNase (Catalog#: D5025, Sigma&#8208;Aldrich, St. Louis, MO). Single cells were obtained by passing digested tissue through a 70&#160;<italic>&#956;</italic>mol/L filter (Catalog#: 352350, Corning, Corning, NY). Red blood cells were removed by lysis in ACK red blood cell lysis buffer (Catalog#: 118&#8208;156&#8208;101, Quality Biological, Gaithersburg, MD) and subsequent centrifugation at 220<italic>g</italic> for 5&#160;min.</p><p>Labeling of cells for cytometry analyses was done according to manufacturers&#8217; recommendations. Briefly, approximately 2&#160;million cells were incubated in 1% BSA containing the following antibodies: eFluor 450 mouse anti&#8208;human CD45 (Catalog#: 48&#8208;9459&#8208;42, 2D1; ThermoFisher Scientific (eBioscience), Waltham, MA), Brilliant Violet 605 mouse anti&#8208;human CD3 (Catalog#: 317322, OKT3; BioLegend, San Diego, CA), PE mouse anti&#8208;human CD4 (Catalog#: 317409, OKT4, BioLegend), APC&#8208;Cy7 mouse anti&#8208;human CD8 (Catalog#:557834, SK1, BD Biosciences, San Jose, CA), and aqua fluorescent reactive dye (L34957; ThermoFisher Scientific (Invitrogen)). Cells were washed with 1% BSA and resuspended in PBS.</p><p>All samples were analyzed on the LSRII flow cytometer (BD Biosciences) and the FlowJo version 10.0 software (FlowJo LLC, Ashland, OR).</p></sec><sec id="phy213951-sec-0005"><title>Flow cytometry of T cells from urine</title><p>The flow cytometry analyses were done from approximately 20&#8211;50&#160;mL of remnant urine samples within 4&#160;h of collection. Cells were isolated by centrifugation at 1200&#160;rpm (220&#160;g) for 10&#160;min. Urine was discarded and the cells were washed with 1% BSA and respun at 1200&#160;rpm for 5&#160;min at 4&#176;C. The isolated cells were stained for 30&#160;min at room temperature with the antibodies (as outlined above in description of labeling of cells from kidney tissues). Cells were spun at 1200&#160;rpm for 5&#160;min at 4&#176;C, washed with BSA, and fixed in 2% PFA for 30&#160;min at room temperature. The labeled cells were resuspended in 1X PBS and analyzed using the LSRII flow cytometer.</p></sec><sec id="phy213951-sec-0006"><title>Immunofluorescence microscopy</title><p>The kidney tissue sections (7&#160;<italic>&#956;</italic>m thick) were washed with 1X PBS, fixed with 4% PFA, and permeabilized with 1% Triton X&#8208;100 for 10&#160;min. These sections were incubated in PBS with 0.2% Triton X&#8208;100 for 10&#160;min followed by blocking with 1% BSA, 2% (vol/vol) donkey serum, and 0.02% sodium azide in PBS for 30&#160;min at room temperature. Samples were then stained overnight at 4&#176;C with the direct&#8208;conjugated primary antibodies CD3&#8208;PE (Catalog #: 12&#8208;0034&#8208;82, OKT3; ThermoFisher Scientific (Invitrogen)) and CD68&#8208;Alexa647 (Catalog #:333819, Y1/82A, Biolegend) diluted in blocking solution. Slides were washed and stained with Hoechst (Sigma&#8208;Aldrich; St. Louis, MO). Coverslips were mounted using Immuno Mount (ThermoFisher Scientific). Images were analyzed using a PerkinElmer ERS 6FE spinning disk confocal microscope (PerkinElmer, Inc., Waltham, MA).</p></sec><sec id="phy213951-sec-0007"><title>Statistical analyses</title><p>Statistical evaluations including outcome distributions and correlations were performed with SPSS 23.0 statistical software package (IBM Corp, Armonk, North Castle, NY.)</p></sec></sec><sec id="phy213951-sec-0008"><title>Results</title><sec id="phy213951-sec-0009"><title>T cell number is increased in ADPKD kidneys</title><p>The flow cytometry analyses of ADPKD (vs. non&#8208;ADPKD) tissues revealed increased numbers of intrarenal CD3 T cells (0.500 vs. 0.081 percent of total renal cells; <italic>P</italic>&#160;=&#160;0.006; Fig.&#160;<xref rid="phy213951-fig-0002" ref-type="fig">2</xref>) as well as their subtypes: CD4 T helper cells (0.189 vs. 0.034; <italic>P</italic>&#160;=&#160;0.014), CD8 cytotoxic T cells (0.249 vs. 0.043; <italic>P</italic>&#160;=&#160;0.008), and double negative (DN) T cells (0.041 vs. 0.004; <italic>P</italic>&#160;=&#160;0.070). The ADPKD&#8208;associated increase in T cells and their subtypes was proportional to the overall increase in intrarenal CD45 leukocytes in ADPKD (vs. non&#8208;ADPKD) kidneys (Fig.&#160;<xref rid="phy213951-fig-0002" ref-type="fig">2</xref>).</p><fig fig-type="Figure" xml:lang="en" id="phy213951-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Total number of renal T cells are increased in <styled-content style="fixed-case">ADPKD</styled-content> kidneys. (A) Representative flow cytometry plots showing <styled-content style="fixed-case">CD</styled-content>3 T cells isolated from <styled-content style="fixed-case">ADPKD</styled-content> and control kidneys (left panel) as well as <styled-content style="fixed-case">CD</styled-content>4 and <styled-content style="fixed-case">CD</styled-content>8 T cells (right panel). (B) Quantification of the total number of <styled-content style="fixed-case">CD</styled-content>3, <styled-content style="fixed-case">CD</styled-content>4, <styled-content style="fixed-case">CD</styled-content>8, and <styled-content style="fixed-case">DN</styled-content> T cells from normal (Black circles) and <styled-content style="fixed-case">ADPKD</styled-content> kidneys (Gray squares) is shown as a percentage of total kidney cells and a percentage of <styled-content style="fixed-case">CD</styled-content>45 immune cells (*<italic>P</italic>&#160;&lt;&#160;0.05, **<italic>P</italic>&#160;&lt;&#160;0.01). Each black circle (non&#8208;<styled-content style="fixed-case">ADPKD</styled-content> controls; <italic>n</italic>&#160;=&#160;7) and each gray square (<styled-content style="fixed-case">ADPKD</styled-content> patients; <italic>n</italic>&#160;=&#160;6) represents a single patient.</p></caption><graphic id="nlm-graphic-5" xlink:href="PHY2-7-e13951-g002"/></fig><p>Data obtained by immunofluorescence microscopy on kidney sections are consistent with that obtained by flow cytometry. Analysis of confocal images shows interstitial CD3 T cell accumulation in ADPKD (vs. non&#8208;ADPKD kidneys), especially in regions containing smaller, presumably developing cysts. (Fig.&#160;<xref rid="phy213951-fig-0003" ref-type="fig">3</xref>). The increase of CD3 T&#8208;cells as well as pattern of their distribution in ADPKD (vs. non&#8208;ADPKD) kidney tissues resembled that of CD68, the human pan&#8208;macrophage marker (Fig.&#160;<xref rid="phy213951-fig-0003" ref-type="fig">3</xref>) (Zeier et&#160;al. <xref rid="phy213951-bib-0019" ref-type="ref">1992</xref>; Swenson&#8208;Fields et&#160;al. <xref rid="phy213951-bib-0016" ref-type="ref">2013</xref>).</p><fig fig-type="Figure" xml:lang="en" id="phy213951-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Interstitial T cell infiltrates are found in areas of small <styled-content style="fixed-case">ADPKD</styled-content> cysts. Representative images demonstrate prominent <styled-content style="fixed-case">CD</styled-content>3 T cell infiltrates as well as <styled-content style="fixed-case">CD</styled-content>68 mononuclear phagocyte infiltrates in renal interstitium surrounding small, presumably developing, cysts. The control and <styled-content style="fixed-case">ADPKD</styled-content> kidney sections were stained with antibodies to detect <styled-content style="fixed-case">CD</styled-content>68 (white; a human pan&#8208;macrophage marker) or <styled-content style="fixed-case">CD</styled-content>3 (red, a pan T cell marker). Arrows depict individual T cells. Scale bar&#160;=&#160;50&#160;<italic>&#956;</italic>m.</p></caption><graphic id="nlm-graphic-7" xlink:href="PHY2-7-e13951-g003"/></fig></sec><sec id="phy213951-sec-0010"><title>ADPKD abrogates polarity of T cell distribution in renal cortex versus medulla</title><p>In normal human kidneys, flow cytometry analyses showed an increase in the number of CD3 T cells and their subtypes (CD4, CD8, and DN T cells) in renal medulla versus cortex (e.g., 0.182 vs. 0.037 for CD3 T cells, <italic>P</italic>&#160;=&#160;0.023; 0.055 vs. 0.019 for CD4 T cells, <italic>P</italic>&#160;=&#160;0.076; 0.112 vs. 0.015 for CD8 T cells, <italic>P</italic>&#160;=&#160;0.038; 0.007 vs. 0.002 for DN T cells, <italic>P</italic>&#160;=&#160;0.017; Fig.&#160;<xref rid="phy213951-fig-0004" ref-type="fig">4</xref>). This polarity was absent in ADPKD (i.e., 0.424 CD3 T cells in medulla vs. 1.039 for in cortex; <italic>P</italic>&#160;=&#160;0.258) due to a suspected influx of T cells into both the cortex and medulla (Fig.&#160;<xref rid="phy213951-fig-0004" ref-type="fig">4</xref>). Overall numbers of CD3+ T cells and their subsets were increased in ADPKD kidneys compared to control kidneys although the number of T cells as a percentage of CD45+ cells was not different suggesting a general influx of immune cells in to the kidney (Fig.&#160;<xref rid="phy213951-fig-0005" ref-type="fig">5</xref>).</p><fig fig-type="Figure" xml:lang="en" id="phy213951-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Influx of T cells to <styled-content style="fixed-case">ADPKD</styled-content> kidneys abrogates normal polarity of T cell distribution in medulla versus cortex. The number of T cells and their subsets in the cortex versus medulla from control (left panel; cortex&#8208; black circles, medulla&#8208; black squares) and <styled-content style="fixed-case">ADPKD</styled-content> kidneys (right panel; cortex&#8208;gray circles; medulla&#8208;gray squares;) is shown as a percentage of total kidney cells. *<italic>P</italic>&#160;&lt;&#160;0.05</p></caption><graphic id="nlm-graphic-9" xlink:href="PHY2-7-e13951-g004"/></fig><fig fig-type="Figure" xml:lang="en" id="phy213951-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>T cell accumulation is increased in renal medulla from <styled-content style="fixed-case">ADPKD</styled-content> patients. (A) The numbers of T cells and their subsets in the cortex and medulla were determined by flow cytometry and are shown as a percentage of total kidney cells (black circles&#8208;control cortex, gray circles&#8208;<styled-content style="fixed-case">ADPKD</styled-content> cortex; black squares&#8208; control medulla, gray squares&#8208; <styled-content style="fixed-case">ADPKD</styled-content> medulla; *<italic>P</italic>&#160;&lt;&#160;0.05). (B) <styled-content style="fixed-case">ADPKD</styled-content> had no effects on the proportion of T cells and their subsets as a percentage of <styled-content style="fixed-case">CD</styled-content>45+ cells.</p></caption><graphic id="nlm-graphic-11" xlink:href="PHY2-7-e13951-g005"/></fig></sec><sec id="phy213951-sec-0011"><title>T cells are present in urine of ADPKD patients and their numbers correlate with rate of renal function loss</title><p>Flow cytometry identified CD3 T cells in 97% (29 of 30) of analyzed urine samples from ADPKD patients with a range 0.04&#8211;360 cells/mL; on average the CD3 T cell subtypes were represented by CD4 (39%), CD8 (48%), and DN (16%) subsets. Evaluation of the associations between urine T cell counts and renal function indices showed moderately strong inverse correlation between eGFR and an index of CD4 cells (<italic>r</italic>&#160;=&#160;&#8722;0.455, <italic>P</italic>&#160;=&#160;0.012). Importantly, there was also a moderately strong correlation between the urine CD4 T cell index and average annual rate of eGFR decline over 5&#160;years (<italic>r</italic>&#160;=&#160;0.411, <italic>P</italic>&#160;=&#160;0.024; Fig.&#160;<xref rid="phy213951-fig-0006" ref-type="fig">6</xref>). Adjustment for urine volume instead of creatinine concentration yielded similar data.</p><fig fig-type="Figure" xml:lang="en" id="phy213951-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Urinary <styled-content style="fixed-case">CD</styled-content>4 cells correlate with <styled-content style="fixed-case">eGFR</styled-content> decline comparably but independently from size of <styled-content style="fixed-case">ADPKD</styled-content> kidneys. (A) Representative flow cytometry plots of CD3 T cell subpopulations in ADPKD patients with similar demographic characteristics and kidney length, but a different rate of eGFR loss over time. The patient with eGFR decline of 5&#160;mL/min/1.73&#160;m<sup>2</sup> per year over 5&#160;years had moderate T cells numbers in the urine, while the patient with stable renal function (eGFR decline 0 over 5&#160;years) had negligible amount of T cells in urine. (B) Correlation between the average yearly eGFR loss and urine CD4&#8208;based indices (bottom panel) are comparable but independent to kidney length (upper left panel); both are superior to urine albumin to creatinine ratio (upper right panel).</p></caption><graphic id="nlm-graphic-13" xlink:href="PHY2-7-e13951-g006"/></fig><p>Interestingly, the strength of correlation between kidney length (KL; recently identified predictor of ADPKD progression (Bhutani et&#160;al. <xref rid="phy213951-bib-0001" ref-type="ref">2015</xref>)) and the renal function indices showed similarly strong associations (e.g., for eGFR <italic>r</italic>&#160;=&#160;0.380; <italic>P</italic>&#160;=&#160;0.038; for the eGFR slope <italic>r</italic>&#160;=&#160;0.400, <italic>P</italic>&#160;=&#160;0.029). However, the T cell indices correlated only weakly with KL (e.g., <italic>r</italic>&#160;=&#160;0.013&#8211;0.295) suggesting independent effects. Urine albumin to creatinine ratio, another predictor of ADPKD progression, correlated inversely with eGFR (<italic>r</italic>&#160;=&#160;&#8722;0.422; <italic>P</italic>&#160;=&#160;0.201); however, its correlation with eGFR slope was weak (<italic>r</italic>&#160;=&#160;0.192; <italic>P</italic>&#160;=&#160;0.309).</p></sec></sec><sec id="phy213951-sec-0012"><title>Discussion</title><p>Similar to the earlier report (Zeier et&#160;al. <xref rid="phy213951-bib-0019" ref-type="ref">1992</xref>), we observed increased interstitial T cell infiltrates in ADPKD (vs. non&#8208;ADPKD) kidneys. However, we now provide a more granular quantitative assessment with flow cytometry&#8208;based quantification of major T cell subtypes.</p><p>Our data complement existing studies that support a potential role of T cells in ADPKD pathogenesis. They include pericystic colocalization of T cells with CD68 mononuclear phagocytes (MPs), a group of cells that modulates renal cystic disease progression in animal models (Karihaloo et&#160;al. <xref rid="phy213951-bib-0006" ref-type="ref">2011</xref>; Swenson&#8208;Fields et&#160;al. <xref rid="phy213951-bib-0016" ref-type="ref">2013</xref>). Functional multilevel interaction between T cells and MPs was well established; although, never before demonstrated in ADPKD. Since both T cells and MPs were more abundant in areas with smaller cysts (vs. larger cysts), it is possible that the interaction of T cells with MPs is important during initiation or early stages of the cyst formation rather than progressive growth of advanced larger cysts.</p><p>While the value of the reported flow cytometry analyses is limited by the relatively small size of ADPKD (<italic>n</italic>&#160;=&#160;6) and non&#8208;ADPKD cohorts (<italic>n</italic>&#160;=&#160;7) that were not optimally matched by gender and race, the presented data are consistent with similar increases in intrarenal T cell subclasses in mouse cystic kidney disease models including the <italic>Pkd1&#160;p.R3277C (Pkd1</italic>
<sup><italic>RC/RC</italic></sup>
<italic>)</italic> mouse that mimics human ADPKD phenotype (Kleczko et&#160;al. <xref rid="phy213951-bib-0008" ref-type="ref">2018</xref>).</p><p>The association of urine T cell indices with eGFR and eGFR slope reported in this manuscript provides additional support for the suggested role of T cells in ADPKD pathogenesis. Moreover, it points to urine T cells as a candidate marker of the disease activity in ADPKD that may complement structural ADPKD outcome predictors (e.g., as total kidney volume based indices). Urine T cells are already recognized as a biomarker for patients with proliferative lupus nephritis and used to monitor treatment response (Enghard et&#160;al. <xref rid="phy213951-bib-0003" ref-type="ref">2009</xref>; Kopetschke et&#160;al. <xref rid="phy213951-bib-0009" ref-type="ref">2015</xref>). Further studies in a larger patient cohort will be required to determine whether urinary T cells can be used as a marker of disease activity and response to therapy in ADPKD. Such biomarkers are sorely needed as the most sensitive approaches currently used to assess ADPKD progression are based on longitudinal follow&#8208;up of total kidney volume (TKV). These data may require imaging many months to years apart to reveal a meaningful difference. The urinary T cell changes may occur more quickly, and their detection may allow for timely adjustments of future ADPKD therapeutics approaches.</p><p>The major limitation of this study is a relatively small size of an ADPKD cohort (<italic>n</italic>&#160;=&#160;30) to evaluate association of urinary T cells with renal function indices. Also, this prospective cohort of consequent clinic patients does not meet the standard of well&#8208;established ADPKD research cohorts that often include germline ADPKD mutations, as well as additional descriptors of the disease activity such as TKV.</p><p>Another limitation is the use of ADPKD kidneys from patients with end&#8208;stage renal disease. These mostly fibrotic kidneys may not accurately reflect ADPKD pathobiology during earlier stages of the disease progression. However, the other potential sources of ADPKD kidney tissues are even more problematic: kidney biopsy is contraindicated in ADPKD and autopsy specimens are relatively rare, influenced by the underlying cause of death and collected over highly variable interval after the death. Instead, we suggest that urine is an important source of intrarenal T cells that can be obtained with minimal risk from ADPKD patients across different stages of the disease progression as we show in the current study.</p><p>In summary, we show that advanced ADPKD is associated with increased intrarenal CD4, CD8, and double negative (DN) T cells. Notably, ADPKD abrogated the normal polarity of intrarenal T cell distribution found in non&#8208;ADPKD controls (low T cell content in renal cortex and high in medulla). While these data were based on tissues obtained from patients with end&#8208;stage ADPKD, we observed nearly identical changes by flow cytometry of T cells from the urine of ADPKD patients. Also, the urinary T cell indices correlated moderately with renal function decline in a small cohort of ADPKD patients. Together, these data suggest that similar to innate immune responses, T cells participate in ADPKD pathogenesis. Also, they point to urinary T cells as a novel candidate marker of the disease activity in ADPKD.</p></sec><sec id="phy213951-sec-0013"><title>Conflict of Interest</title><p>M. M. reports grants and consulting fees outside the submitted work from Otsuka Pharmaceuticals and Sanofi.</p></sec></body><back><ref-list content-type="cited-references" id="phy213951-bibl-0001"><title>References</title><ref id="phy213951-bib-0001"><mixed-citation publication-type="journal" id="phy213951-cit-0001">
<string-name>
<surname>Bhutani</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Smith</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Rahbari&#8208;Oskoui</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Mittal</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Grantham</surname>
</string-name>, <string-name>
<given-names>V. E.</given-names>
<surname>Torres</surname>
</string-name>, et&#160;al. <year>2015</year>
<article-title>A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease</article-title>. <source xml:lang="en">Kidney Int.</source>
<volume>88</volume>:<fpage>146</fpage>&#8211;<lpage>151</lpage>.<pub-id pub-id-type="pmid">25830764</pub-id></mixed-citation></ref><ref id="phy213951-bib-0002"><mixed-citation publication-type="journal" id="phy213951-cit-0002">
<string-name>
<surname>Cowley</surname>, <given-names>B. D.</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<given-names>S. D.</given-names>
<surname>Ricardo</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Nagao</surname>
</string-name>, and <string-name>
<given-names>J. R.</given-names>
<surname>Diamond</surname>
</string-name>. <year>2001</year>
<article-title>Increased renal expression of monocyte chemoattractant protein&#8208;1 and osteopontin in ADPKD in rats</article-title>. <source xml:lang="en">Kidney Int.</source>
<volume>60</volume>:<fpage>2087</fpage>&#8211;<lpage>2096</lpage>.<pub-id pub-id-type="pmid">11737583</pub-id></mixed-citation></ref><ref id="phy213951-bib-0003"><mixed-citation publication-type="journal" id="phy213951-cit-0003">
<string-name>
<surname>Enghard</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Humrich</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Rudolph</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Rosenberger</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Biesen</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kuhn</surname>
</string-name>, et&#160;al. <year>2009</year>
<article-title>CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients</article-title>. <source xml:lang="en">Arthritis Rheum.</source>
<volume>60</volume>:<fpage>199</fpage>&#8211;<lpage>206</lpage>.<pub-id pub-id-type="pmid">19116922</pub-id></mixed-citation></ref><ref id="phy213951-bib-0004"><mixed-citation publication-type="journal" id="phy213951-cit-0004">
<string-name>
<surname>Fernando</surname>, <given-names>M. R.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Dent</surname>
</string-name>, <string-name>
<given-names>S. P.</given-names>
<surname>McDonald</surname>
</string-name>, and <string-name>
<given-names>G. K.</given-names>
<surname>Rangan</surname>
</string-name>. <year>2017</year>
<article-title>Incidence and survival of end&#8208;stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963&#8208;2014)</article-title>. <source xml:lang="en">Popul. Health Metr.</source>
<volume>15</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">28212688</pub-id></mixed-citation></ref><ref id="phy213951-bib-0005"><mixed-citation publication-type="journal" id="phy213951-cit-0005">
<string-name>
<surname>Grantham</surname>, <given-names>J. J.</given-names>
</string-name>, <string-name>
<given-names>V. E.</given-names>
<surname>Torres</surname>
</string-name>, <string-name>
<given-names>A. B.</given-names>
<surname>Chapman</surname>
</string-name>, <string-name>
<given-names>K. T.</given-names>
<surname>Bae</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Tao</surname>
</string-name>, <string-name>
<given-names>L. M.</given-names>
<surname>Guay&#8208;Woodford</surname>
</string-name>, et&#160;al. <year>2010</year>
<article-title>Urinary monocyte chemotactic protein&#8208;1 (MCP1) predicts progression in autosomal dominant polycystic kidney disease (ADPKD)</article-title>. <source xml:lang="en">J. Am. Soc. Nephrol.</source>
<volume>21</volume>:<fpage>526A</fpage>.</mixed-citation></ref><ref id="phy213951-bib-0006"><mixed-citation publication-type="journal" id="phy213951-cit-0006">
<string-name>
<surname>Karihaloo</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Koraishy</surname>
</string-name>, <string-name>
<given-names>S. C.</given-names>
<surname>Huen</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Merrick</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Caplan</surname>
</string-name>, et&#160;al. <year>2011</year>
<article-title>Macrophages promote cyst growth in polycystic kidney disease</article-title>. <source xml:lang="en">J. Am. Soc. Nephrol.</source>
<volume>22</volume>:<fpage>1809</fpage>&#8211;<lpage>1814</lpage>.<pub-id pub-id-type="pmid">21921140</pub-id></mixed-citation></ref><ref id="phy213951-bib-0007"><mixed-citation publication-type="journal" id="phy213951-cit-0007">
<string-name>
<surname>Kaspareit&#8208;Rittinghausen</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Rapp</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Deerberg</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Wcislo</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Messow</surname>
</string-name>. <year>1989</year>
<article-title>Hereditary polycystic kidney disease associated with osteorenal syndrome in rats</article-title>. <source xml:lang="en">Vet. Pathol.</source>
<volume>26</volume>:<fpage>195</fpage>&#8211;<lpage>201</lpage>.<pub-id pub-id-type="pmid">2763410</pub-id></mixed-citation></ref><ref id="phy213951-bib-0008"><mixed-citation publication-type="journal" id="phy213951-cit-0008">
<string-name>
<surname>Kleczko</surname>, <given-names>E. K.</given-names>
</string-name>, <string-name>
<given-names>K. H.</given-names>
<surname>Marsh</surname>
</string-name>, <string-name>
<given-names>L. C.</given-names>
<surname>Tyler</surname>
</string-name>, <string-name>
<given-names>S. B.</given-names>
<surname>Furgeson</surname>
</string-name>, <string-name>
<given-names>B. L.</given-names>
<surname>Bullock</surname>
</string-name>, <string-name>
<given-names>C. J.</given-names>
<surname>Altmann</surname>
</string-name>, et&#160;al. <year>2018</year>
<article-title>CD8+ T cells modulate autosomal dominant polycystic kidney disease progression</article-title>. <source xml:lang="en">Kidney Int.</source>
<volume>94</volume>:<fpage>1127</fpage>&#8211;<lpage>1140</lpage>.<pub-id pub-id-type="pmid">30249452</pub-id></mixed-citation></ref><ref id="phy213951-bib-0009"><mixed-citation publication-type="journal" id="phy213951-cit-0009">
<string-name>
<surname>Kopetschke</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Klocke</surname>
</string-name>, <string-name>
<given-names>A. S.</given-names>
<surname>Griessbach</surname>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Humrich</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Biesen</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Dragun</surname>
</string-name>, et&#160;al. <year>2015</year>
<article-title>The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers</article-title>. <source xml:lang="en">Arthritis Res. Ther.</source>
<volume>17</volume>:<fpage>94</fpage>.<pub-id pub-id-type="pmid">25890061</pub-id></mixed-citation></ref><ref id="phy213951-bib-0010"><mixed-citation publication-type="journal" id="phy213951-cit-0010">
<string-name>
<surname>Li</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<given-names>B. S.</given-names>
<surname>Magenheimer</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Xia</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Johnson</surname>
</string-name>, <string-name>
<given-names>D. P.</given-names>
<surname>Wallace</surname>
</string-name>, <string-name>
<given-names>J. P.</given-names>
<surname>Calvet</surname>
</string-name>, et&#160;al. <year>2008</year>
<article-title>A tumor necrosis factor&#8208;alpha&#8208;mediated pathway promoting autosomal dominant polycystic kidney disease</article-title>. <source xml:lang="en">Nat. Med.</source>
<volume>14</volume>:<fpage>863</fpage>&#8211;<lpage>868</lpage>.<pub-id pub-id-type="pmid">18552856</pub-id></mixed-citation></ref><ref id="phy213951-bib-0011"><mixed-citation publication-type="journal" id="phy213951-cit-0011">
<string-name>
<surname>Mei</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Xiong</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Jia</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Hu</surname>
</string-name>, et&#160;al. <year>2007</year>
<article-title>Experimental research on the treatment of autosomal dominant polycystic kidney disease with mycophenolate mofetil</article-title>. <source xml:lang="en">J. Am. Soc. Nehrol.</source>
<volume>18</volume>:<fpage>364A</fpage>.</mixed-citation></ref><ref id="phy213951-bib-0012"><mixed-citation publication-type="journal" id="phy213951-cit-0012">
<string-name>
<surname>Mrug</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Mrug</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Landsittel</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Torres</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Bae</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Harris</surname>
</string-name>, et&#160;al. <year>2013a</year>
<article-title>Prediction of GFR endpoints in early autosomal dominant polycystic kidney disease</article-title>. <source xml:lang="en">Am. J. Nephrol.</source>
<volume>24</volume>:<fpage>59A</fpage>.</mixed-citation></ref><ref id="phy213951-bib-0013"><mixed-citation publication-type="journal" id="phy213951-cit-0013">
<string-name>
<surname>Mrug</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>L. M.</given-names>
<surname>Guay&#8208;Woodford</surname>
</string-name>, and <string-name>
<given-names>L. E.</given-names>
<surname>Smythies</surname>
</string-name>. <year>2013b</year>
<article-title>Renal macrophages in autosomal recessive polycystic kidney disease</article-title>. <source xml:lang="en">Nephrology</source>
<volume>18</volume>:<fpage>746</fpage>.<pub-id pub-id-type="pmid">24571748</pub-id></mixed-citation></ref><ref id="phy213951-bib-0014"><mixed-citation publication-type="journal" id="phy213951-cit-0014">
<string-name>
<surname>Shillingford</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<given-names>N. S.</given-names>
<surname>Murcia</surname>
</string-name>, <string-name>
<given-names>C. H.</given-names>
<surname>Larson</surname>
</string-name>, <string-name>
<given-names>S. H.</given-names>
<surname>Low</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Hedgepeth</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Brown</surname>
</string-name>, et&#160;al. <year>2006</year>
<article-title>The mTOR pathway is regulated by polycystin&#8208;1, and its inhibition reverses renal cystogenesis in polycystic kidney disease</article-title>. <source xml:lang="en">Proc. Natl Acad. Sci. USA</source>
<volume>103</volume>:<fpage>5466</fpage>&#8211;<lpage>5471</lpage>.<pub-id pub-id-type="pmid">16567633</pub-id></mixed-citation></ref><ref id="phy213951-bib-0015"><mixed-citation publication-type="journal" id="phy213951-cit-0015">
<string-name>
<surname>Spithoven</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kramer</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Meijer</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Orskov</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Wanner</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Caskey</surname>
</string-name>, et&#160;al. <year>2014</year>
<article-title>Analysis of data from the ERA&#8208;EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease</article-title>. <source xml:lang="en">Kidney Int.</source>
<volume>86</volume>:<fpage>1244</fpage>&#8211;<lpage>1252</lpage>.<pub-id pub-id-type="pmid">24827775</pub-id></mixed-citation></ref><ref id="phy213951-bib-0016"><mixed-citation publication-type="journal" id="phy213951-cit-0016">
<string-name>
<surname>Swenson&#8208;Fields</surname>, <given-names>K. I.</given-names>
</string-name>, <string-name>
<given-names>C. J.</given-names>
<surname>Vivian</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Salah</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Peda</surname>
</string-name>, <string-name>
<given-names>B. M.</given-names>
<surname>Davis</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>van Rooijen</surname>
</string-name>, et&#160;al. <year>2013</year>
<article-title>Macrophages promote polycystic kidney disease progression</article-title>. <source xml:lang="en">Kidney Int.</source>
<volume>83</volume>:<fpage>855</fpage>&#8211;<lpage>864</lpage>.<pub-id pub-id-type="pmid">23423256</pub-id></mixed-citation></ref><ref id="phy213951-bib-0017"><mixed-citation publication-type="journal" id="phy213951-cit-0017">
<string-name>
<surname>Takahashi</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Calvet</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Dittemore&#8208;Hoover</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Yoshida</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Grantham</surname>
</string-name>, and <string-name>
<given-names>V.</given-names>
<surname>Gattone</surname>
</string-name>. <year>1991</year>
<article-title>A hereditary model of slowly progressive polycystic kidney disease in the mouse</article-title>. <source xml:lang="en">J. Am. Soc. Nephrol.</source>
<volume>1</volume>:<fpage>980</fpage>&#8211;<lpage>989</lpage>.<pub-id pub-id-type="pmid">1883968</pub-id></mixed-citation></ref><ref id="phy213951-bib-0018"><mixed-citation publication-type="journal" id="phy213951-cit-0018">
<string-name>
<surname>Vogler</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Homan</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Pung</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Thorpe</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Barker</surname>
</string-name>, <string-name>
<given-names>E. H.</given-names>
<surname>Birkenmeier</surname>
</string-name>, et&#160;al. <year>1999</year>
<article-title>Clinical and pathologic findings in two new allelic murine models of polycystic kidney disease</article-title>. <source xml:lang="en">J. Am. Soc. Nephrol.</source>
<volume>10</volume>:<fpage>2534</fpage>&#8211;<lpage>2539</lpage>.<pub-id pub-id-type="pmid">10589692</pub-id></mixed-citation></ref><ref id="phy213951-bib-0019"><mixed-citation publication-type="journal" id="phy213951-cit-0019">
<string-name>
<surname>Zeier</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Fehrenbach</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Geberth</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Mohring</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Waldherr</surname>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Ritz</surname>
</string-name>. <year>1992</year>
<article-title>Renal histology in polycystic kidney disease with incipient and advanced renal failure</article-title>. <source xml:lang="en">Kidney Int.</source>
<volume>42</volume>:<fpage>1259</fpage>&#8211;<lpage>1265</lpage>.<pub-id pub-id-type="pmid">1453612</pub-id></mixed-citation></ref><ref id="phy213951-bib-0020"><mixed-citation publication-type="journal" id="phy213951-cit-0020">
<string-name>
<surname>Zheng</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Wolfe</surname>
</string-name>, <string-name>
<given-names>B. D.</given-names>
<suffix>Jr</suffix>
<surname>Cowley</surname>
</string-name>, <string-name>
<given-names>D. P.</given-names>
<surname>Wallace</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Yamaguchi</surname>
</string-name>, and <string-name>
<given-names>J. J.</given-names>
<surname>Grantham</surname>
</string-name>. <year>2003</year>
<article-title>Urinary excretion of monocyte chemoattractant protein&#8208;1 in autosomal dominant polycystic kidney disease</article-title>. <source xml:lang="en">J. Am. Soc. Nephrol.</source>
<volume>14</volume>:<fpage>2588</fpage>&#8211;<lpage>2595</lpage>.<pub-id pub-id-type="pmid">14514736</pub-id></mixed-citation></ref><ref id="phy213951-bib-0021"><mixed-citation publication-type="journal" id="phy213951-cit-0021">
<string-name>
<surname>Zhou</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Ouyang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Cui</surname>
</string-name>, <string-name>
<given-names>T. R.</given-names>
<surname>Schoeb</surname>
</string-name>, <string-name>
<given-names>L. E.</given-names>
<surname>Smythies</surname>
</string-name>, <string-name>
<given-names>M. R.</given-names>
<surname>Johnson</surname>
</string-name>, et&#160;al. <year>2010</year>
<article-title>Renal CD14 expression correlates with the progression of cystic kidney disease</article-title>. <source xml:lang="en">Kidney Int.</source>
<volume>78</volume>:<fpage>550</fpage>&#8211;<lpage>560</lpage>.<pub-id pub-id-type="pmid">20555320</pub-id></mixed-citation></ref></ref-list></back></article>